Therapeutic Advances in Endometrial Microbiome Modulation

Abstract

The endometrial microbiome, once thought to be a sterile environment, is now recognized as a dynamic ecosystem influencing female reproductive health. Recent advances have illuminated the profound impact of microbial dysbiosis on gynecological conditions such as infertility, recurrent pregnancy loss, chronic endometritis, and endometrial cancer. This review synthesizes up-to-date evidence on the epidemiology, pathophysiology, risk factors, clinical manifestations, and diagnostic approaches related to endometrial microbiome disturbances. Emphasis is placed on therapeutic interventions, with particular focus on microbiome-modulating strategies, their clinical efficacy, underlying mechanisms, and evolving practice guidelines. We also discuss future directions and research priorities for optimizing reproductive outcomes through targeted microbiome modulation.

Introduction

The paradigm shift recognizing the endometrium as a non-sterile compartment has propelled research into the interplay between microbial communities and endometrial health. The composition and diversity of the endometrial microbiome are increasingly implicated in reproductive pathologies and treatment outcomes, especially in the context of assisted reproductive technologies (ART). Understanding the mechanistic links between microbial signatures and endometrial receptivity provides a foundation for novel therapeutic approaches. This article aims to provide clinicians and researchers with an in-depth analysis of current knowledge and emerging strategies for endometrial microbiome modulation.

Epidemiology / Disease Burden

Dysbiosis of the endometrial microbiome is prevalent among women with infertility, recurrent implantation failure, and chronic endometritis, with studies reporting abnormal microbial profiles in up to 30–50% of affected individuals. Globally, infertility affects approximately 8–12% of couples, with endometrial factors accounting for a significant proportion. The recognition of microbial imbalance as a modifiable risk factor highlights the potential for population-level impact through targeted interventions. Furthermore, chronic endometritis, often subclinical, is increasingly diagnosed in women undergoing evaluation for unexplained infertility or recurrent pregnancy loss, further underscoring the burden of endometrial microbiota disturbances.

Pathophysiology

The healthy endometrial microbiome is typically dominated by Lactobacillus species, which contribute to immune homeostasis, maintenance of mucosal barrier integrity, and suppression of pathogenic bacteria. Dysbiosis, characterized by the depletion of Lactobacilli and enrichment of anaerobic pathogens such as Gardnerella, Atopobium, and Prevotella, promotes chronic inflammation, disrupts endometrial receptivity, and impairs embryo implantation. Mechanistically, microbial metabolites, including short-chain fatty acids and lipopolysaccharides, modulate local cytokine profiles, immune cell recruitment, and epithelial function. These alterations are associated with aberrant decidualization, endometrial remodeling, and heightened susceptibility to infection and neoplastic transformation.

Risk Factors

Multiple factors predispose to endometrial microbiome dysbiosis, including frequent antibiotic use, hormonal imbalances, intrauterine device (IUD) insertion, prior uterine surgery, and sexual practices that alter vaginal flora. Systemic conditions such as diabetes mellitus and obesity may also indirectly influence the uterine microbial environment via immune and metabolic pathways. Genetic susceptibility, environmental exposures, and lifestyle factors further modulate the risk, necessitating individualized assessment in clinical practice.

Clinical Features

Clinical manifestations of endometrial microbiome disturbances range from asymptomatic states to overt reproductive dysfunction. Chronic endometritis may present with abnormal uterine bleeding, pelvic discomfort, or remain clinically silent, discovered only during infertility workup. In ART settings, dysbiosis is associated with recurrent implantation failure, reduced clinical pregnancy rates, and increased miscarriage risk. In rare cases, severe microbial imbalance may contribute to the pathogenesis of endometrial hyperplasia or malignancy, typically in conjunction with other risk factors.

Diagnosis

Accurate diagnosis of endometrial microbiome dysbiosis requires a combination of clinical, histopathological, and molecular approaches. Endometrial sampling, typically via pipelle biopsy, enables microbiological culture, immunohistochemical staining for plasma cells (CD138), and advanced sequencing techniques such as 16S rRNA gene analysis and metagenomic shotgun sequencing. These methods provide insights into microbial diversity, abundance, and functional potential. Quantitative PCR assays targeting specific pathogenic taxa and assessment of inflammatory biomarkers further refine diagnostic sensitivity and specificity.

Treatment & Management

Therapeutic strategies for endometrial microbiome modulation encompass antibiotic regimens, probiotic supplementation, and, more recently, prebiotic and synbiotic formulations. Empirical antibiotic treatment, often guided by microbial profiling, is employed for chronic endometritis and cases of ART failure associated with dysbiosis. Probiotics, particularly Lactobacillus strains, are under investigation for their ability to restore eubiosis and enhance endometrial receptivity. Hormonal therapies may indirectly influence microbial composition by modulating mucosal immunity. Individualized therapy, informed by microbial and clinical parameters, is recommended for optimizing reproductive outcomes.

Recent Advances / Emerging Therapies

Recent research has focused on precision microbiome interventions, including next-generation probiotics, microbiota transplantation, and targeted bacteriophage therapy. Pilot studies of intrauterine microbiota transfer and engineered Lactobacillus strains show promise in restoring microbial balance and improving ART success rates. Advances in multi-omics and machine learning are enabling the identification of predictive microbial signatures and personalized treatment algorithms. Ongoing clinical trials are evaluating the efficacy and safety of novel agents, with particular attention to long-term reproductive and oncologic outcomes.

Guideline Recommendations

Current international guidelines acknowledge the importance of endometrial microbiome assessment in women with unexplained infertility, recurrent pregnancy loss, and repeated ART failure. The European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) recommend consideration of endometrial sampling and treatment of confirmed chronic endometritis. However, routine microbiome screening and broad probiotic use await further validation from large-scale randomized controlled trials. Clinicians are advised to individualize therapy based on clinical context, microbial findings, and patient preferences.

Conclusion

Modulation of the endometrial microbiome represents a frontier in reproductive medicine with significant clinical potential. Evidence supports the role of microbial dysbiosis in a spectrum of gynecological disorders, and emerging therapies offer hope for improving outcomes in challenging cases of infertility and ART failure. While antibiotic and probiotic strategies are gaining traction, ongoing research is needed to define optimal regimens, candidate populations, and long-term benefits. Multidisciplinary collaboration and integration of advanced diagnostic tools will be crucial for translating scientific advances into routine clinical practice.